Open Source Drug Discovery

Last updated

Open Source Drug Discovery is a Council of Scientific and Industrial Research, India (CSIR)-led Team India Consortium with global participation [1] [2] [3] [4] [5] offering a collaborative drug discovery platform for neglected tropical diseases like leishmaniasis, which draw limited attention of research-based pharmaceutical enterprises. [1] [5] [6] [7] [8] This program has a global community with over 7500 participants from 130 countries comprising researchers, academia, students, industries, educational institutions and so on. [7] [9] Anyone who is committed to the discovery of drugs for neglected diseases in an open source mode can participate in the program. [10] OSDD functions by bringing together experts from diverse backgrounds to focus on discovering and developing affordable drugs for tropical infections.

Contents

History

CSIR-OSDD was launched in September 2008. [9] [11] This project was conceived by Prof Samir K. Brahmachari, the Founder Director of CSIR-Institute of Genomics and Integrative Biology as an 11th Five year plan project of CSIR. [12] This was approved by the Government of India with an overall outlay of Rs 45.96 crores (about $12 million). [13] The project motto is “Affordable healthcare for all” and makes use of open source philosophy, crowd –sourcing concepts and a collaborative research model, [14] capitalizing on web based tools to fuel innovation and discover novel therapies. [13] [15] All the data and resources generated by the community are openly shared through a web based portal called Sysborg 2.0 specifically designed for this purpose [5] [16] [17]

The project has a healthcare model that blends together the policies of patenting and open source research, aiming to make novel drugs available as generic drugs, [18] without Intellectual Property restrictions, and thus ensure affordability and accessibility. [1] [5] [19]

The first action involved development of drugs for tuberculosis (TB) bacillus ( Mycobacterium tuberculosis ). [20] The project has two phases:

  1. Phase I (2008–2012) which will involve discovery and development of new drugs.
  2. Phase II (2012–2017) which will involve clinical trials.

Process

OSDD started with the set up of a web portal, which is based on the Wiki model of website so that participating agencies can easily contribute to or modify the content of the website. The information uploaded can be then peer-reviewed. New drugs being developed will be in public domain. The generic drugs will be taken up by pharmaceutical companies so that the drug will be commercialised at reasonable price. [21]

Operational methodology

The process of drug discovery is divided into ten work packages, namely [21]

  1. WP1 - Drug target identification. This promotes computational activities including Systems Biology research for identification of potential drug targets. It opens participation of academia, institutions and industries with strong inclination towards open source.
  2. WP2 - Expression of targets. This involves sharing experimental results on potential drug targets and development of assays.
  3. WP3 - Screen development. This involves the use of specific assays developed for different targets to screen large chemical compound libraries.
  4. WP4 - In silico docking. This involves determining the target and identification of potential sites on the hit compounds for synthesis of analogs, so that maximum potency and minimum toxicity are achieved.
  5. WP5 - Micro array gene expression for human cells and tissues with the best inhibitors. This involves identification of compounds with higher binding affinity for the target without altering expression profile of host cell.
  6. WP6 - Medicinal chemistry. This includes synthesis of improved compounds.
  7. WP7 - Lead optimization. This is to produce lead compounds with desirable effects while unaffecting the host.
  8. WP8 - Proteomics based lead affinity column to check for human cellular protein binding
  9. WP9 - Pre-clinical toxicity of the lead compounds
  10. WP10 - Clinical development of new molecular entities

Work packages 1–8 are within Phase I, while WP9 and 10 are within Phase II.

Organisation

OSDD is a collaborative project and a unit of CSIR. Prof.Samir K. Brahmachari, Former Director General of CSIR is the "Chief Mentor" of the Open Source Drug Discovery Project. M. Vijayan, President of the Gyan Bindu Academy , V. M. Katoch, Director General of the Indian Council of Medical Research (ICMR), and N.K. Ganguli, former Director General of ICMR, are the Mentors. Individual projects are taken up by participating bodies and are managed by a Principal Investigator. [21] These projects are centrally supervised by the OSDD project director Dr Sarala Balachandran at CSIR.

Funding

The core funding of OSDD is from the Government of India. For the period of September 2008 to March 2012, Government of India had earmarked Rs 45.96 crores (about $12 million) for the project. [22] The funds are used for funding the scientific projects, setting up infrastructure, and supporting ongoing activities of the project. [23] Up to 2012, OSDD was a project under ‘National Laboratories Scheme’ of CSIR. For the 12th five-year plan during 2013-2017, the planning commission has approved the continuation of OSDD as a part of Scheme for Open Innovation of CSIR.

Achievements

OSDD is joined by 7,500 registered participants from different parts of the world. There are about 110 research projects being carried out. The collaborative work has identified more than 60 potential drug targets of M. tuberculosis. There are seven targets that are being examined. The first international publication of the consortium was in 2009 on the integrative genomics map of M. tuberculosis. [24] Since then more than a dozen of research are published. [25] OSDD currently operates the OSDD Chemistry outreach programme (OSDDChem). Under this system, students are trained in synthetic chemistry and the compounds synthesized in the universities, institutes and colleges in OSDDChem centres are submitted to the OSDDChem database and sent to CSIR-CDRI. These molecules are then taken up for screening at CSIR-CDRI for anti-TB and anti-malarial activity. [26] [27]

See also

Related Research Articles

<span class="mw-page-title-main">Tropical medicine</span> Interdisciplinary branch of medicine

Tropical medicine is an interdisciplinary branch of medicine that deals with health issues that occur uniquely, are more widespread, or are more difficult to control in tropical and subtropical regions.

<span class="mw-page-title-main">Drug development</span> Process of bringing a new pharmaceutical drug to the market

Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery. It includes preclinical research on microorganisms and animals, filing for regulatory status, such as via the United States Food and Drug Administration for an investigational new drug to initiate clinical trials on humans, and may include the step of obtaining regulatory approval with a new drug application to market the drug. The entire process – from concept through preclinical testing in the laboratory to clinical trial development, including Phase I–III trials – to approved vaccine or drug typically takes more than a decade.

The Structural Genomics Consortium (SGC) is a public-private-partnership focusing on elucidating the functions and disease relevance of all proteins encoded by the human genome, with an emphasis on those that are relatively understudied. The SGC places all its research output into the public domain without restriction and does not file for patents and continues to promote open science. Two recent publications revisit the case for open science. Founded in 2003, and modelled after the Single Nucleotide Polymorphism Database (dbSNP) Consortium, the SGC is a charitable company whose Members comprise organizations that contribute over $5,4M Euros to the SGC over a five-year period. The Board has one representative from each Member and an independent Chair, who serves one 5-year term. The current Chair is Anke Müller-Fahrnow (Germany), and previous Chairs have been Michael Morgan (U.K.), Wayne Hendrickson (U.S.A.), Markus Gruetter (Switzerland) and Tetsuyuki Maruyama (Japan). The founding and current CEO is Aled Edwards (Canada). The founding Members of the SGC Company were the Canadian Institutes of Health Research, Genome Canada, the Ontario Research Fund, GlaxoSmithKline and Wellcome Trust. The current Members comprise Bayer Pharma AG, Bristol Myers Squibb, Boehringer Ingelheim, the Eshelman Institute for Innovation, Genentech, Genome Canada, Janssen, Merck KGaA, Pfizer, and Takeda.

<span class="mw-page-title-main">Drugs for Neglected Diseases Initiative</span> Non-profit organization

The Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients' needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected diseases, notably leishmaniasis, sleeping sickness, Chagas disease, malaria, filarial diseases, mycetoma, paediatric HIV, cryptococcal meningitis, hepatitis C, and dengue. DNDi's malaria activities were transferred to Medicines for Malaria Venture (MMV) in 2015.

The Institute of Microbial Technology (IMTECH), based in Chandigarh, India, is one of the constituent establishments of the Council of Scientific & Industrial Research (CSIR). It was established in 1984.

The Novartis Institute for Tropical Disease (NITD) was a Singapore-based tropical disease research institute created through a public-private partnership between Novartis and the Singapore Economic Development Board. Research at NITD focuses primarily on developing novel small molecule therapies for tropical infectious diseases that are endemic to the developing world, particularly dengue fever, malaria and tuberculosis.

Samir Kumar Brahmachari is an Indian biophysicist and Former Director General of the Council of Scientific & Industrial Research (CSIR) and Former Secretary, Department of Scientific and Industrial Research (DSIR), Government of India. He is the Founder Director of Institute of Genomics and Integrative Biology (IGIB), New Delhi and the Chief Mentor of Open Source for Drug Discovery (OSDD) Project. He is the recipient of J.C Bose Fellowship Award, DST (2012). In addition, he is one of the featured researchers in the India Cancer Research Database developed by Institute of Bioinformatics (IOB), Bangalore with support from the Department of Biotechnology, Government of India.

ZAMBART Project is a public health research non-governmental organization conducting scientific research into the dual epidemics of tuberculosis and HIV. The organization is based in Lusaka, Zambia at the University of Zambia's School of Medicine Ridgeway Campus. ZAMBART has over 200 employees and works in 16 study sites throughout the country.

Computational Resources for Drug Discovery (CRDD) is one of the important silico modules of Open Source for Drug Discovery (OSDD). The CRDD web portal provides computer resources related to drug discovery on a single platform. It provides computational resources for researchers in computer-aided drug design, a discussion forum, and resources to maintain a wiki related to drug discovery, predict inhibitors, and predict the ADME-Tox property of molecules. One of the major objectives of CRDD is to promote open source software in the field of chemoinformatics and pharmacoinformatics.

<span class="mw-page-title-main">Lupin Limited</span> Indian multinational pharmaceutical company

Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is one of the largest generic pharmaceutical companies by revenue globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

<span class="mw-page-title-main">Garikapati Narahari Sastry</span> Indian chemist

Garikapati Narahari Sastry is an Indian chemist. He has taken charge as Director of CSIR-North East Institute of Science and Technology, Jorhat, Assam on 19 February 2019. After taking charge as the Director, he has worked towards converting knowledge in the areas of computational modelling and Artificial intelligence from basic to translational research, by working closely with society and industry. Ultimately, revitalizing the strength of science and technology is essential in achieving the self-reliant and strong India. In the era of Industry 4.0 and 5.0, combining our traditional wisdom with modern science appear to be indispensable in the sectors such as Education, Health, Agriculture, Industrial and Societal development at large. Prior to joining as the Director, he headed the Molecular Modelling Division at the CSIR Indian Institute of Chemical Technology in Hyderabad, India. Sastry has made pioneering contributions in the areas of computational chemistry and computational biology.

<span class="mw-page-title-main">Sean Ekins</span>

Sean Ekins is a British pharmacologist and expert in the fields of ADME/Tox, computational toxicology and cheminformatics at Collaborations in Chemistry, a division of corporate communications firm Collaborations in Communications. He is also the editor of four books and a book series for John Wiley & Sons.

Totally drug-resistant tuberculosis (TDR-TB) is a generic term for tuberculosis strains that are resistant to a wider range of drugs than strains classified as extensively drug-resistant tuberculosis. Extensively drug resistant tuberculosis is tuberculosis that is resistant to isoniazid and rifampicin, any fluoroquinolone, and any of the three second line injectable TB drugs. TDR-TB has been identified in three countries; India, Iran, and Italy. The term was first presented in 2006, in which it showed that TB was resistant to many second line drugs and possibly all the medicines used to treat the disease. Lack of testing made it unclear which drugs the TDR-TB were resistant to.

Mitali Mukerji is a Professor and Head of the Department of Bioscience and Bioengineering, IIT Jodhpur. She was formerly a Chief Scientist at the CSIR Institute of Genomics and Integrative Biology with notable achievement in the field of human genomics and personalized medicine. She is best known for initiating the field of "Ayurgenomics" in partnership with her colleague Dr. Bhavana Prasher under the mentorship of Prof. Samir K. Brahmachari. Ayurgenomics is an innovative study, blending the principles of Ayurveda- the traditional Indian system of medicine- with genomics. Mukerji is also a major contributor in the Indian Genome Variation Consortium, a comprehensive database that is producing "the first genetic landscape of the Indian population", and has been an author in many publications that use IGV databases to study population genomics. Mukerji has done extensive research on hereditary ataxias, and is involved in many other projects related to tracking disease origins and mutational histories. She is the recipient of the prestigious Shanti Swarup Bhatnagar Award in 2010 for her contribution in the field of Medical Sciences.

The Global Health Innovative Technology Fund, headquartered in Japan, is an international public-private partnership between the Government of Japan, 16 pharmaceutical and diagnostics companies, the Bill & Melinda Gates Foundation, the Wellcome Trust and United Nations Development Programme. It funds scientific research and development for anti-infectives and diagnostics for diseases that primarily affect the developing world. Bill Gates has noted that "GHIT draws on the immense innovation capacity of Japan’s pharmaceutical companies, universities and research institutions to accelerate the creation of new vaccines, drugs and diagnostic tools for global health." Margaret Chan, former Director-General of the World Health Organization, said: "The GHIT Fund has stepped in to provide that incentive in a pioneering model of partnership that brings Japanese innovation, investment and leadership to the global fight against infectious disease."

Vinod Bhakuni (1962–2011) was an Indian molecular biophysicist and the head of the Molecular and Structural Biology Division of the Central Drug Research Institute (CDRI). He was the founder of the Protein Chemistry laboratory of CDRI and was known for his contributions to the study of protein folding. A recipient of the National Bioscience Award for Career Development, he was an elected fellow of the Indian Academy of Sciences, Indian National Science Academy and the National Academy of Sciences, India. The Council of Scientific and Industrial Research, the apex agency of the Government of India for scientific research, awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology, one of the highest Indian science awards, in 2006, for his contributions to biological sciences.

<span class="mw-page-title-main">Anil Koul</span> Indian scientist (born 1972)

Anil Koul is a scientist and former Director of the CSIR-Institute of Microbial Technology (IMTECH), a premier biomedical and biotechnology research institution under Council of Scientific and Industrial Research (CSIR) under Ministry of Science and Technology, Govt. of India.

Debasis Dash is an Indian computational biologist and chief scientist at the Institute of Genomics and Integrative Biology (IGIB). Known for his research on proteomics and Big Data and Artificial Intelligence studies, his studies have been documented by way of a number of articles and ResearchGate, an online repository of scientific articles has listed 120 of them. The Department of Biotechnology of the Government of India awarded him the National Bioscience Award for Career Development, one of the highest Indian science awards, for his contributions to biosciences, in 2014. He is appointed as the director of Institute of Life Sciences, Bhubaneswar on 18 May 2023.

Ashwani Kumar is an Indian microbiologist and the Senior Principal Scientist at the Institute of Microbial Technology (ImTech). He is known for his studies on Mycobacterium tuberculosis, the causative agent of tuberculosis. His laboratory focuses on understanding the reasons for drug tolerance observed in humans. His laboratory hypothesizes that tuberculosis is a biofilm infection, so its treatment needs the administration of multiple drugs for at least six months. The Department of Science and Technology has awarded him Swarnajayanti Fellowship for 2016–2017. Department of Biotechnology has awarded him the National Bioscience Prize (2017-18). He was also selected for DBT/Wellcome Trust India Alliance Senior Fellowship. He was elected as a Fellow of the National Academy of Sciences, India, in 2022. For his contributions in tuberculosis pathogenesis, he was awarded with Shanti Swarup Bhatnagar Prize for Science and Technology 2022. He is considered as one of India's Leading Scientist in the field of Tuberculosis and his lab is doing some of the best research in India.

<span class="mw-page-title-main">Matthew Todd (chemist)</span> British chemist (born 1973)

Matthew Houghton Todd is a British chemist and the Professor and Chair of Drug Discovery of the School of Pharmacy at University College London. He is the founder of Open Source Malaria (OSM) and his research focuses on drug discovery and development for this disease. Recently, he has expanded to other areas, particularly neglected diseases such as tuberculosis and mycetoma in the Open Source Tuberculosis (OSTB) and Open Source Mycetoma (MycetOS) project, through a collaboration with the Drugs for Neglected Diseases Initiative and Erasmus MC. In addition, he has some research activity in catalysis and methodology.

References

  1. 1 2 3 Bhardwaj, Anshu; Scaria, Vinod; Raghava, Gajendra Pal Singh; Lynn, Andrew Michael; Chandra, Nagasuma; Banerjee, Sulagna; Raghunandanan, Muthukurussi V.; Pandey, Vikas; Taneja, Bhupesh; Yadav, Jyoti; Dash, Debasis; Bhattacharya, Jaijit; Misra, Amit; Kumar, Anil; Ramachandran, Srinivasan; Thomas, Zakir; Brahmachari, Samir K.; Brahmachari, S. K. (2011). "Open source drug discovery– A new paradigm of collaborative research in tuberculosis drug development". Tuberculosis. 91 (5): 479–486. doi:10.1016/j.tube.2011.06.004. PMID   21782516. S2CID   5556982.
  2. ↑ Årdal, Christine; Røttingen, John-Arne (2012-09-20). "PLOS Neglected Tropical Diseases: Open Source Drug Discovery in Practice: A Case Study". PLOS Neglected Tropical Diseases. Plosntds.org. 6 (9): e1827. doi: 10.1371/journal.pntd.0001827 . PMC   3447952 . PMID   23029588.
  3. ↑ Pallava Bagla (2012-02-24). "Crowd-Sourcing Drug Discovery". Science. Sciencemag.org. 335 (6071): 909. Bibcode:2012Sci...335..909B. doi:10.1126/science.335.6071.909. PMID   22362985.
  4. ↑ Deepa Kurup (2010-12-17). "Embrace open source philosophy, Kalam tells scientists, researchers". The Hindu. Thehindu.com. Retrieved 2015-04-30.
  5. 1 2 3 4 "OPEN SOURCE DRUG DISCOVERY: A GLOBAL COLLABORATIVE DRUG DISCOVERY MODEL FOR TUBERCULOSIS" (PDF). Scienceandculture-isna.org\accessdate=2015-04-30.
  6. ↑ Dhruba Jyoti Purkait (12 May 2013). "Where are the drugs for tropical diseases? | Business Line". Thehindubusinessline.com. Retrieved 2015-04-30.
  7. 1 2 "Virtual collaboration by researchers could reduce cost of developing life-saving drugs - Business Today". Businesstoday.intoday.in. 2013-01-06. Retrieved 2015-04-30.
  8. ↑ "Open Source Drug Discovery (OSDD)". Openhealthnews.com. Retrieved 2015-04-30.
  9. 1 2 "Govt to rope in young minds to invent cheaper drugs - timesofindia-economictimes". Articles.economictimes.indiatimes.com. 2007-12-20. Retrieved 2015-04-30.
  10. ↑ "Join the movement - Open Source Drug Discovery". Osdd.net. Retrieved 2015-04-30.
  11. ↑ Seema Singh (April 2008). "India Takes an Open Source Approach to Drug Discovery". Cell. 133 (2): 201–203. doi: 10.1016/j.cell.2008.04.003 . PMID   18423188.
  12. ↑ "Samir Brahmachari - Fierce's Top 10 Biotech Techies". FierceBiotechit.com. 2012-03-23. Retrieved 2015-04-30.
  13. 1 2 "About Us - Open Source Drug Discovery". Osdd.net. Retrieved 2015-04-30.
  14. ↑ "Open source drug discovery - timesofindia-economictimes". Articles.economictimes.indiatimes.com. 2007-12-21. Retrieved 2015-04-30.
  15. ↑ Sachin S Rawat (2013-03-05). "Open Source Drug Discovery | Dreamer Biologist". Dreamerbiologist.wordpress.com. Retrieved 2015-04-30.
  16. ↑ "OSDD – Single Sign-On Service". Sysborg2.osdd.net. Retrieved 2015-04-30.
  17. ↑ "Jaimon Joseph's Blog : A Facebook for Labcoats". Ibnlive.in.com. 2011-09-23. Archived from the original on 2011-09-26. Retrieved 2015-04-30.
  18. ↑ "Pvt pharma firms knock CSIR to develop TB drug". The Times of India . 2011-04-15. Archived from the original on 2014-01-07. Retrieved 2015-04-30.
  19. ↑ "Open Source Drug Discovery (OSDD)". Zunia.org. 2012-03-02. Retrieved 2015-04-30.
  20. ↑ Press Information Bureau (15 September 2008). "CSIR launches Open Source Drug Discovery: A Path-Breaking Research Of The People, By The People, For The People". dst.gov.in. Department of Science and Technology, India. Retrieved 7 January 2014.
  21. 1 2 3 Project Director, Open Source Drug Discovery. ""OPEN SOURCE DRUG DISCOVERY" AN OPEN COLLABORATIVE DRUG DISCOVERY MODEL FOR TUBERCULOSIS" (PDF). www.who.int. World Health Organization, Geneva. Retrieved 7 January 2014.
  22. ↑ "Centre commits Rs.150 cr funding to CSIR's Open Source Drug Discovery project | CSIR in the news". Csirindia.wordpress.com. 2011-05-27. Retrieved 2015-04-30.
  23. ↑ "Forbes India Magazine - How Open Source Drug Discovery Is Helping India Develop New Drugs". Forbesindia.com. Retrieved 2015-04-30.
  24. ↑ Bhardwaj, A; Bhartiya, D; Kumar, N; Open Source Drug Discovery Consortium; Scaria, V (2009). "TBrowse: An integrative genomics map of Mycobacterium tuberculosis". Tuberculosis (Edinburgh, Scotland). 89 (5): 386–7. doi:10.1016/j.tube.2009.07.005. PMID   19683474.
  25. ↑ NCBI. "Open Source Drug Discovery Consortium [Corporate Author]". www.ncbi.nlm.nih.gov. National Center for Biotechnology Information, U.S. National Library of Medicine. Retrieved 7 January 2014.
  26. ↑ Himanshi Dhawan (18 September 2013). "CSIR pushes for TB, malaria drug finds". The Times of India . Bennett, Coleman & Co. Ltd. Archived from the original on 20 September 2013. Retrieved 7 January 2014.
  27. ↑ "Open Pharma Project". open-pharma.org. Retrieved 2021-06-25.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.